Yang Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yang Yu has a total of 172 co-authors. Here are the top co-authors by number of shared publications:
- Deqing Wang
Medical School of Chinese PLA, Beijing 100853, PR China; Department of Blood Transfusion Medicine, The First Medical Center, Chinese PLA General Hospital, Beijing 100853, PR China
17 shared publications Lu Yang
Department of Transfusion Medicine, First Medical Center of Chinese PLA General Hospital, Beijing, 100853, China
7 shared publicationsChunya Ma
Department of Transfusion Medicine, First Medical Center of Chinese PLA General Hospital, Beijing, 100853, China
5 shared publications- Chunya Ma
Department of Transfusion Medicine The First Medical Center of Chinese PLA General Hospital Beijing China
5 shared publications Leiying Zhang
Department of Transfusion Medicine The First Medical Center of Chinese PLA General Hospital Beijing China
5 shared publicationsLiping Sun
Department of Transfusion Medicine, First Medical Center of Chinese PLA General Hospital, Beijing, 100853, China
5 shared publications
Latest Publications
- Open Access
- 10 July 2026
- Published by Elsevier in SSRN Electronic Journal
Anemia Impairs Non-small Cell Lung Cancer Immunotherapy Efficacy through CD8+ T Cell Dysfunction
Background; Non-small cell lung cancer (NSCLC) remains a major cause of cancer-related mortality worldwide. Immune checkpoint inhibitors (ICIs) targeting the programmed cell death protein-1/programmed death-ligand 1 (PD-1/PD-L1) axis have significantly improved NSCLC outcomes. However, anemia can reshape the tumor microenvironment (TME) and compromise the efficacy of ICIs. The underlying immunological mechanisms remain largely unknown. This study aimed to elucidate the impact of anemia on NSCLC immunotherapy outcomes and its associated immune alterations.Methods: A retrospective analysis of a multicenter Chinese NSCLC immunotherapy cohort was conducted to compare clinical characteristics and outcomes between patients with and without anemia. Multiplex immunohistochemistry (mIHC) was performed to delineate immune cell distribution within the TME. Anemia was induced in mice using phenylhydrazine, followed by orthotopic implantation of Lewis lung carcinoma (LLC) cells. Tumor growth was longitudinally monitored using micro-CT. At the study endpoint, tumor and spleen tissues were collected for flow cytometry and immunohistochemistry to profile immune cell subsets. Intra-tumoral CD8+ T cells were subsequently isolated for whole-transcriptome sequencing, and their functional relevance was validated by CD8+ T-cell depletion in anemic mice.Results: Anemia was identified as an independent predictor of unfavorable immunotherapy outcomes in NSCLC. Anemic patients (n=162) exhibited significantly shorter survival than non-anemic patients (n=870) (median OS: 15.2m vs. 21.6 m; p = 0.013). Anemic Patients (n=13) vs. non-anemic patients (n=26) exhibited a higher proportion of PD-1+CD8+ T cells within the TME. In anemic mice, anti-PD-1 therapy unexpectedly enhanced tumor growth, accompanied by impaired cytotoxic T-cell infiltration and increased M2-like macrophage polarization. Transcriptomic data revealed suppressed DNA damage repair and cell-cycle pathways in intra-tumoral CD8+ T cells. In anemic mice, anti-PD-1 therapy accelerated tumor progression, while concomitant CD8α depletion failed to further enhance it, suggesting that CD8+ T cells were already functionally exhausted.Conclusion: Anemia independently predicts poor response to immunotherapy in NSCLC, primarily through CD8+ T-cell dysfunction within the TME. These findings highlight anemia-associated immune dysregulation as a potential therapeutic target to optimize immunotherapy efficacy in NSCLC.
- 10 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessAnemia Impairs Non-small Cell Lung Cancer Immunotherapy Efficacy through CD8+ T Cell Dysfunction
Background; Non-small cell lung cancer (NSCLC) remains a major cause of cancer-related mortality worldwide. Immune checkpoint inhibitors (ICIs) targeting the programmed cell death protein-1/programmed death-ligand 1 (PD-1/PD-L1) axis have significantly improved NSCLC outcomes. However, anemia can reshape the tumor microenvironment (TME) and compromise the efficacy of ICIs. The underlying immunological mechanisms remain largely unknown. This study aimed to elucidate the impact of anemia on NSCLC immunotherapy outcomes and its associated immune alterations.Methods: A retrospective analysis of a multicenter Chinese NSCLC immunotherapy cohort was conducted to compare clinical characteristics and outcomes between patients with and without anemia. Multiplex immunohistochemistry (mIHC) was performed to delineate immune cell distribution within the TME. Anemia was induced in mice using phenylhydrazine, followed by orthotopic implantation of Lewis lung carcinoma (LLC) cells. Tumor growth was longitudinally monitored using micro-CT. At the study endpoint, tumor and spleen tissues were collected for flow cytometry and immunohistochemistry to profile immune cell subsets. Intra-tumoral CD8+ T cells were subsequently isolated for whole-transcriptome sequencing, and their functional relevance was validated by CD8+ T-cell depletion in anemic mice.Results: Anemia was identified as an independent predictor of unfavorable immunotherapy outcomes in NSCLC. Anemic patients (n=162) exhibited significantly shorter survival than non-anemic patients (n=870) (median OS: 15.2m vs. 21.6 m; p = 0.013). Anemic Patients (n=13) vs. non-anemic patients (n=26) exhibited a higher proportion of PD-1+CD8+ T cells within the TME. In anemic mice, anti-PD-1 therapy unexpectedly enhanced tumor growth, accompanied by impaired cytotoxic T-cell infiltration and increased M2-like macrophage polarization. Transcriptomic data revealed suppressed DNA damage repair and cell-cycle pathways in intra-tumoral CD8+ T cells. In anemic mice, anti-PD-1 therapy accelerated tumor progression, while concomitant CD8α depletion failed to further enhance it, suggesting that CD8+ T cells were already functionally exhausted.Conclusion: Anemia independently predicts poor response to immunotherapy in NSCLC, primarily through CD8+ T-cell dysfunction within the TME. These findings highlight anemia-associated immune dysregulation as a potential therapeutic target to optimize immunotherapy efficacy in NSCLC.
- Open Access
Diagnosis of Acute Hemolytic Transfusion Reaction Caused by Cold Reactive Anti‐P1 Antibody: A Case Report
Anti‐P1 alloantibody is predominantly an immunoglobulin M class, cold reactive antibody that is non‐reactive at 37°C in routine pre‐transfusion serology and thus generally regarded as clinically insignificant. However, rare clinically significant anti‐P1 antibodies can cause an acute hemolytic transfusion reaction (AHTR), and routine pre‐transfusion testing at 37°C may miss such antibodies. We report a case of AHTR caused by an anti‐P1 antibody detectable only at 4°C, which evaded detection by unexpected antibody screening performed at 37°C. A 65‐year‐old woman with blood group B, RhD positive developed AHTR within 24 h following red blood cell transfusion. She presented with coffee‐colored urine, markedly elevated bilirubin and lactate dehydrogenase concentrations, and a progressive decline in hemoglobin concentrations. Pre‐transfusion antibody screening at 37°C was negative. A retrospective serological analysis identified anti‐P1 exclusively at 4°C, which was confirmed by pigeon egg white inhibition. The patient was P1 negative; incompatibility occurred only with the P1‐positive donor unit. After transfusion of P1 antigen‐negative red blood cells, the hemolysis resolved and hemoglobin concentrations recovered. In patients with a repeated transfusion history, serological testing at 37°C and 4°C, in conjunction with antigen‐matched selection, is essential to prevent AHTR caused by clinically significant cold reactive antibodies.
Open AccessDiagnosis of Acute Hemolytic Transfusion Reaction Caused by Cold Reactive Anti‐P1 Antibody: A Case Report
Anti‐P1 alloantibody is predominantly an immunoglobulin M class, cold reactive antibody that is non‐reactive at 37°C in routine pre‐transfusion serology and thus generally regarded as clinically insignificant. However, rare clinically significant anti‐P1 antibodies can cause an acute hemolytic transfusion reaction (AHTR), and routine pre‐transfusion testing at 37°C may miss such antibodies. We report a case of AHTR caused by an anti‐P1 antibody detectable only at 4°C, which evaded detection by unexpected antibody screening performed at 37°C. A 65‐year‐old woman with blood group B, RhD positive developed AHTR within 24 h following red blood cell transfusion. She presented with coffee‐colored urine, markedly elevated bilirubin and lactate dehydrogenase concentrations, and a progressive decline in hemoglobin concentrations. Pre‐transfusion antibody screening at 37°C was negative. A retrospective serological analysis identified anti‐P1 exclusively at 4°C, which was confirmed by pigeon egg white inhibition. The patient was P1 negative; incompatibility occurred only with the P1‐positive donor unit. After transfusion of P1 antigen‐negative red blood cells, the hemolysis resolved and hemoglobin concentrations recovered. In patients with a repeated transfusion history, serological testing at 37°C and 4°C, in conjunction with antigen‐matched selection, is essential to prevent AHTR caused by clinically significant cold reactive antibodies.
- Open Access
Retrospective Analysis of Blood Donor Deferral Reasons and Optimization Suggestions for Deferral Policies
Background: Blood donor deferral is a critical safeguard to protect both donor health and transfusion safety. However, deferral practices can adversely affect blood availability and donor retention. The aim of this study is to evaluate deferral patterns among voluntary blood donors and to identify opportunities to optimize deferral strategies. Methods: Deferral data were retrospectively collected from the blood transfusion management system of a single center between January 2019 and December 2023. Statistical analyses were performed using SPSS version 25, with p < 0.001 considered statistically significant. Results: A total of 148,282 blood donors were included, of whom 18,343 (12.37%) were deferred. Temporary deferrals accounted for 10.95% (16,240/148,282) and permanent deferrals for 1.42% (2103/148,282). The leading causes of temporary deferral were abnormal alanine aminotransferase (ALT) levels, representing 51.33% (9415/18,343) of all deferrals, followed by low hemoglobin levels at 12.20% (2237/18,343), lipemic blood at 7.12% (1306/18,343), non‐medical reasons including time constraints, procedural complexity, and psychological concerns at 6.90% (1265/18,343), hypertension at 4.08% (749/18,343), and medication use at 2.26% (414/18,343). Permanent deferrals were most frequently attributed to hepatitis B surface antigen (HBsAg) positivity at 4.12% (755/18,343) and syphilis antibody positivity at 2.89% (530/18,343), while nucleic acid reactivity accounted for 0.26% (48/18,343). Conclusion: Targeted donor education, optimization of pre‐donation screening, and refinement of deferral criteria may improve donor recruitment and retention while maintaining transfusion safety.
Open AccessRetrospective Analysis of Blood Donor Deferral Reasons and Optimization Suggestions for Deferral Policies
Background: Blood donor deferral is a critical safeguard to protect both donor health and transfusion safety. However, deferral practices can adversely affect blood availability and donor retention. The aim of this study is to evaluate deferral patterns among voluntary blood donors and to identify opportunities to optimize deferral strategies. Methods: Deferral data were retrospectively collected from the blood transfusion management system of a single center between January 2019 and December 2023. Statistical analyses were performed using SPSS version 25, with p < 0.001 considered statistically significant. Results: A total of 148,282 blood donors were included, of whom 18,343 (12.37%) were deferred. Temporary deferrals accounted for 10.95% (16,240/148,282) and permanent deferrals for 1.42% (2103/148,282). The leading causes of temporary deferral were abnormal alanine aminotransferase (ALT) levels, representing 51.33% (9415/18,343) of all deferrals, followed by low hemoglobin levels at 12.20% (2237/18,343), lipemic blood at 7.12% (1306/18,343), non‐medical reasons including time constraints, procedural complexity, and psychological concerns at 6.90% (1265/18,343), hypertension at 4.08% (749/18,343), and medication use at 2.26% (414/18,343). Permanent deferrals were most frequently attributed to hepatitis B surface antigen (HBsAg) positivity at 4.12% (755/18,343) and syphilis antibody positivity at 2.89% (530/18,343), while nucleic acid reactivity accounted for 0.26% (48/18,343). Conclusion: Targeted donor education, optimization of pre‐donation screening, and refinement of deferral criteria may improve donor recruitment and retention while maintaining transfusion safety.
- Open Access
- 31 December 2025
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 245, 152-167
Riboflavin photochemical therapy triggered PANoptosis by inducing mitochondrial damage in circulating colorectal cancer cells
- 31 December 2025
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 245, 152-167
Open AccessRiboflavin photochemical therapy triggered PANoptosis by inducing mitochondrial damage in circulating colorectal cancer cells
- Open Access
- 22 December 2025
- Published by Elsevier in Journal of Photochemistry and Photobiology B: Biology
- Vol. 274, 113347
Ultraviolet-treated riboflavin induces ROS-mediated apoptosis via inhibiting mitochondrial complex I in acute myeloid leukemia
- 22 December 2025
- Published by Elsevier in Journal of Photochemistry and Photobiology B: Biology
- Vol. 274, 113347
Open AccessUltraviolet-treated riboflavin induces ROS-mediated apoptosis via inhibiting mitochondrial complex I in acute myeloid leukemia
- Open Access
A Rare Case of Delayed Hemolytic Transfusion Reaction Caused by Anti‐Ku: Laboratory Diagnosis and Clinical Management
This study presents a rare case of delayed hemolytic transfusion reaction (DHTR) induced by anti‐Ku. The patient was admitted due to recurrence of ovarian cancer. She had experienced unexplained anemia for more than 20 years but had no anemia in the past 10 years. She had been pregnant four times and given birth to four babies without blood transfusions. Pre‐transfusion examinations showed that her blood group was A and RhD positive, and the unexpected antibody screening test was weakly reactive. She received two red blood cell transfusions and then developed unexplained anemia, with a hemoglobin decrease from 122 to 88 g/L. The unexpected antibody screening result changed to strongly positive, and she returned positive direct anti‐human globulin test and major incompatible matching results. The homozygous mutation 715G > T was identified in exon 7 of the KELL gene, which is associated with a rare blood group phenotype known as K 0 . The patient produced anti‐Ku antibodies, leading to a DHTR. Extravascular hemolysis was controlled through the administration of immunoglobulin and erythropoietin, leading to the correction of anemia. Her hemoglobin concentration was 105 g/L upon discharge from the hospital. In the management of blood transfusion for patients with rare blood types, a comprehensive analysis is required, taking into account the specificity of high‐frequency antibodies produced by the patient, the types and strength of these antibodies, as well as the clinical demand for blood. When necessary, a short‐term, adequate transfusion of minimally incompatible blood may be administered, along with intravenous immunoglobulin and erythropoietin to correct hemolysis and anemia.
Open AccessA Rare Case of Delayed Hemolytic Transfusion Reaction Caused by Anti‐Ku: Laboratory Diagnosis and Clinical Management
This study presents a rare case of delayed hemolytic transfusion reaction (DHTR) induced by anti‐Ku. The patient was admitted due to recurrence of ovarian cancer. She had experienced unexplained anemia for more than 20 years but had no anemia in the past 10 years. She had been pregnant four times and given birth to four babies without blood transfusions. Pre‐transfusion examinations showed that her blood group was A and RhD positive, and the unexpected antibody screening test was weakly reactive. She received two red blood cell transfusions and then developed unexplained anemia, with a hemoglobin decrease from 122 to 88 g/L. The unexpected antibody screening result changed to strongly positive, and she returned positive direct anti‐human globulin test and major incompatible matching results. The homozygous mutation 715G > T was identified in exon 7 of the KELL gene, which is associated with a rare blood group phenotype known as K 0 . The patient produced anti‐Ku antibodies, leading to a DHTR. Extravascular hemolysis was controlled through the administration of immunoglobulin and erythropoietin, leading to the correction of anemia. Her hemoglobin concentration was 105 g/L upon discharge from the hospital. In the management of blood transfusion for patients with rare blood types, a comprehensive analysis is required, taking into account the specificity of high‐frequency antibodies produced by the patient, the types and strength of these antibodies, as well as the clinical demand for blood. When necessary, a short‐term, adequate transfusion of minimally incompatible blood may be administered, along with intravenous immunoglobulin and erythropoietin to correct hemolysis and anemia.
- Open Access
Evaluation of Effectiveness and Safety of Apheresis Autologous Red Blood Cell Technology in Patients Undergoing Spinal Surgery: A Single‐Center Randomized Controlled Trial
Background: Pre‐operative autologous blood donation (PAD) is increasingly used in spinal surgery because of the risk of substantial intraoperative blood loss. However, evidence on the effectiveness and safety of apheresis autologous red blood cell (RBC) technology remains limited. This study was conducted to evaluate whether this technology can reduce allogeneic transfusion in spinal surgery without adverse effects. Methods: In this randomized, two‐group, unblinded clinical trial, participants undergoing spinal surgery between November 2018 and September 2023 were randomized 1∶1 to receive apheresis autologous RBCs (auto‐RBC group, n = 30) or standard allogeneic transfusion (allo‐RBC group, n = 30). The two primary outcomes were allogeneic RBC transfusion and postoperative length of hospitalization. Twenty‐eight secondary outcomes and 12 safety indicators were also assessed. Results: Of the 60 randomized patients, 47 completed the trial. The allogeneic RBC transfusion rate was significantly lower in the auto‐RBC group than in the allo‐RBC group (39.1% vs. 70.8%, p = 0.041). Intraoperative allogeneic RBC transfusion volume was also significantly reduced (0.50 ± 1.16 vs. 1.50 ± 1.69 U, p = 0.023). No significant difference was found in postoperative hospitalization (7.48 ± 0.80 vs. 9.21 ± 2.41 d, p = 0.461). Of the 28 prespecified secondary outcomes, 25 showed no significant between‐group differences. Hemoglobin on postoperative day 3 was lower in the auto‐RBC group (91.09 ± 2.99 vs. 100.00 ± 2.91 g/L, p = 0.039). Hemoglobin in the auto‐RBC group also declined from pre‐apheresis to preoperative levels (144.65 ± 10.86 vs. 122.56 ± 14.60 g/L, p < 0.001). Conclusions: Apheresis autologous RBC technology reduces the rate of allogeneic RBC transfusion in major spinal surgeries without increasing hospitalization or complications. These findings support its use in adult patients undergoing major spinal procedures.
Open AccessEvaluation of Effectiveness and Safety of Apheresis Autologous Red Blood Cell Technology in Patients Undergoing Spinal Surgery: A Single‐Center Randomized Controlled Trial
Background: Pre‐operative autologous blood donation (PAD) is increasingly used in spinal surgery because of the risk of substantial intraoperative blood loss. However, evidence on the effectiveness and safety of apheresis autologous red blood cell (RBC) technology remains limited. This study was conducted to evaluate whether this technology can reduce allogeneic transfusion in spinal surgery without adverse effects. Methods: In this randomized, two‐group, unblinded clinical trial, participants undergoing spinal surgery between November 2018 and September 2023 were randomized 1∶1 to receive apheresis autologous RBCs (auto‐RBC group, n = 30) or standard allogeneic transfusion (allo‐RBC group, n = 30). The two primary outcomes were allogeneic RBC transfusion and postoperative length of hospitalization. Twenty‐eight secondary outcomes and 12 safety indicators were also assessed. Results: Of the 60 randomized patients, 47 completed the trial. The allogeneic RBC transfusion rate was significantly lower in the auto‐RBC group than in the allo‐RBC group (39.1% vs. 70.8%, p = 0.041). Intraoperative allogeneic RBC transfusion volume was also significantly reduced (0.50 ± 1.16 vs. 1.50 ± 1.69 U, p = 0.023). No significant difference was found in postoperative hospitalization (7.48 ± 0.80 vs. 9.21 ± 2.41 d, p = 0.461). Of the 28 prespecified secondary outcomes, 25 showed no significant between‐group differences. Hemoglobin on postoperative day 3 was lower in the auto‐RBC group (91.09 ± 2.99 vs. 100.00 ± 2.91 g/L, p = 0.039). Hemoglobin in the auto‐RBC group also declined from pre‐apheresis to preoperative levels (144.65 ± 10.86 vs. 122.56 ± 14.60 g/L, p < 0.001). Conclusions: Apheresis autologous RBC technology reduces the rate of allogeneic RBC transfusion in major spinal surgeries without increasing hospitalization or complications. These findings support its use in adult patients undergoing major spinal procedures.
- Open Access
- 20 March 2025
- Published by Elsevier in Biochemical Pharmacology
- Vol. 236, 116879
Ultraviolet-treated riboflavin alleviates atopic dermatitis by inhibiting NLRP3 inflammasome activation and M1 macrophage polarization via histone lactylation
- 20 March 2025
- Published by Elsevier in Biochemical Pharmacology
- Vol. 236, 116879
Open AccessUltraviolet-treated riboflavin alleviates atopic dermatitis by inhibiting NLRP3 inflammasome activation and M1 macrophage polarization via histone lactylation
- Open Access
- 17 March 2025
- Published by Wolters Kluwer Health in Blood Science
- Vol. 7 (2) , e00209
Expression profiles and potential roles of microRNAs in erythrocytes during the aging process
Studies have shown that microRNAs (miRNAs) in red blood cells (RBCs) contribute most of the miRNAs in whole blood, and miRNAs in RBCs are closely related to storage lesions in vitro. However, the role of miRNAs in the process of RBC senescence in vivo remains unclear. We conducted a comprehensive miRNA expression analysis of RBCs collected from enriched mature RBCs in five density layers. The results showed that the type and number of RBC miRNAs changed with the aging of RBCs, the expression levels of 10 RBC miRNAs decreased markedly at the early stage of RBC aging and the levels of 5 RBC miRNAs increased significantly at the terminal stage of RBC senescence. The analysis identified 32 miRNAs whose changes in expression levels were correlated with the two selected aging indexes—pyruvate kinase (PK) activity and RBC indices. The differential expression amounts of the two selected miRNAs (miR-22-3p and miR-144-3p) were confirmed by real-time polymerase chain reaction (PCR) analysis. A bioinformatics analysis identified the potential targets and biological functions of these miRNAs. The experiment of miR-22-3p in the human erythroblast cell line K562 confirmed its negative effects on PK levels. Overall, our research demonstrates, for the first time, that changes in the expression levels of miRNAs during the RBC aging process, and RBC miRNAs thus have the potential to serve as markers of RBC aging in vivo. In addition, the expression of miR-22-3p may regulate RBC senescence by inhibiting PK levels.
- 17 March 2025
- Published by Wolters Kluwer Health in Blood Science
- Vol. 7 (2) , e00209
Open AccessExpression profiles and potential roles of microRNAs in erythrocytes during the aging process
Studies have shown that microRNAs (miRNAs) in red blood cells (RBCs) contribute most of the miRNAs in whole blood, and miRNAs in RBCs are closely related to storage lesions in vitro. However, the role of miRNAs in the process of RBC senescence in vivo remains unclear. We conducted a comprehensive miRNA expression analysis of RBCs collected from enriched mature RBCs in five density layers. The results showed that the type and number of RBC miRNAs changed with the aging of RBCs, the expression levels of 10 RBC miRNAs decreased markedly at the early stage of RBC aging and the levels of 5 RBC miRNAs increased significantly at the terminal stage of RBC senescence. The analysis identified 32 miRNAs whose changes in expression levels were correlated with the two selected aging indexes—pyruvate kinase (PK) activity and RBC indices. The differential expression amounts of the two selected miRNAs (miR-22-3p and miR-144-3p) were confirmed by real-time polymerase chain reaction (PCR) analysis. A bioinformatics analysis identified the potential targets and biological functions of these miRNAs. The experiment of miR-22-3p in the human erythroblast cell line K562 confirmed its negative effects on PK levels. Overall, our research demonstrates, for the first time, that changes in the expression levels of miRNAs during the RBC aging process, and RBC miRNAs thus have the potential to serve as markers of RBC aging in vivo. In addition, the expression of miR-22-3p may regulate RBC senescence by inhibiting PK levels.
- Open Access
- 21 December 2024
- Published by Springer Nature in Inflammation
- Vol. 48 (4) , 2503-2515
CircIRAK3 Promotes Neutrophil Extracellular Trap Formation by Improving the Stability of ELANE mRNA in Sepsis
Excessive formation of neutrophil extracellular traps (NETs) has been shown to exacerbate inflammatory injury and organ damage in patients with sepsis. Circular RNAs (circRNAs) abnormally expressed in immune cells of sepsis patients, and play an important role in the pathogenesis of dysregulated immune responses. However, the functions of circRNAs in NET formation during sepsis remain unknown. Here, we identified circIRAK3, a novel circRNA that was upregulated in peripheral blood neutrophils of sepsis patients. Combining clinical data, we revealed that elevated circIRAK3 was positively correlated with blood NET levels. Furthermore, knockdown and overexpression in differentiated HL-60 (dHL-60) neutrophil-like cells demonstrated that circIRAK3 promoted NET formation. In addition, we found that circIRAK3 promoted NET formation via positively regulating elastase expression in dHL-60 cells when treated with inflammatory stimuli. Mechanistically, circIRAK3 directly interacted with ELAVL1 to improve ELANE mRNA stability and consequently promote elastase protein expression. In summary, our study reveals that circIRAK3 promotes NET formation in sepsis by increasing ELANE mRNA levels.
- 21 December 2024
- Published by Springer Nature in Inflammation
- Vol. 48 (4) , 2503-2515
Open AccessCircIRAK3 Promotes Neutrophil Extracellular Trap Formation by Improving the Stability of ELANE mRNA in Sepsis
Excessive formation of neutrophil extracellular traps (NETs) has been shown to exacerbate inflammatory injury and organ damage in patients with sepsis. Circular RNAs (circRNAs) abnormally expressed in immune cells of sepsis patients, and play an important role in the pathogenesis of dysregulated immune responses. However, the functions of circRNAs in NET formation during sepsis remain unknown. Here, we identified circIRAK3, a novel circRNA that was upregulated in peripheral blood neutrophils of sepsis patients. Combining clinical data, we revealed that elevated circIRAK3 was positively correlated with blood NET levels. Furthermore, knockdown and overexpression in differentiated HL-60 (dHL-60) neutrophil-like cells demonstrated that circIRAK3 promoted NET formation. In addition, we found that circIRAK3 promoted NET formation via positively regulating elastase expression in dHL-60 cells when treated with inflammatory stimuli. Mechanistically, circIRAK3 directly interacted with ELAVL1 to improve ELANE mRNA stability and consequently promote elastase protein expression. In summary, our study reveals that circIRAK3 promotes NET formation in sepsis by increasing ELANE mRNA levels.